Business UpdateJun 22, 2026, 07:31 AM
Medicus Pharma to Present SkinJect®, Teverelix® Updates at Bio Conference
AI Summary
Medicus Pharma Ltd. announced its participation in the 2026 Bio International Conference, where Chief Medical Officer Dr. Faisal Mehmud will present updates on the company's clinical, regulatory, and strategic advancements. The presentation will highlight positive Phase 2 results for SkinJect® in basal cell carcinoma, ongoing FDA interactions, and regulatory initiatives for Gorlin Syndrome. Additionally, updates on Teverelix® will include progress in advanced prostate cancer, acute urinary retention relapse, and the newly initiated PRECISION-E2 Phase 2a study for endometriosis.
Key Highlights
- Medicus Pharma to participate in the 2026 Bio International Conference from June 22-25, 2026.
- Dr. Faisal Mehmud will present updates on SkinJect® and Teverelix® development programs.
- SkinJect® Phase 2 SKNJCT-003 study showed 55% histological clearance and 64% clinical clearance.
- SkinJect® for Gorlin Syndrome has Orphan Drug and Rare Pediatric Disease designations under FDA review.
- Teverelix® advanced prostate cancer program has a planned Phase 2b dose-optimization study in the EU.
- Teverelix® initiated PRECISION-E2 Phase 2a study in endometriosis leveraging the UAE Genome Program.
- Company strategy focuses on advancing programs through Phase 2 de-risking for potential partnerships.
Price Impact
More from MDCX